Quiz-summary
0 of 1 questions completed
Questions:
- 1
Information
Presented by George Netto, M.D. and prepared by Amy Duffield, M.D., Ph.D.
Case 5: A 62 year old male was found to have a 3.2 renal mass on imaging studies.
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading...
You must sign in or sign up to start the quiz.
You have to finish following quiz, to start this quiz:
Results
Time has elapsed
Categories
- Not categorized 0%
- 1
- Answered
- Review
-
Question 1 of 1
1. Question
Week 377: Case 5
A 62 year old male was found to have a 3.2 renal mass on imaging studies performed for right flank pain. A partial Nephrectomy was performed.images/01_05_2009 5A.jpg
images/01_05_2009 5B.jpg
images/01_05_2009 5C.jpg
images/01_05_2009 5D.jpg
images/01_05_2009 5E.jpgCorrect
Answer: Angiomyolipoma (AML)
Histology: see below
Discussion: Fat-rich angiomyolipoma are more easily diagnosed as AML on imaging studies and are therefore only rarely resected. Fat-poor examples, like the current case, are more difficult to diagnose especially at the time of frozen section, a point to remember when examining a frozen section from “tumor bed” margin during partial nephrectomy.
A member of the perivascular epithelioid cell (PEComa) group of neoplasms, renal angiomyolipomas (AML) represent 1% of renal masses. One third of AML are associated with tuberous sclerosis (TSC) syndrome. When present, the characteristic histologic triad of thick walled vessels + mature fat + smooth muscle fibers make for an easy diagnosis. However, the occasional presence of focal cytologic pleomorphism especially when coupled with hemorrhage and ensuing necrosis can lead to overdiagnosis as a sarcomatoid renal cell carcinoma. Immunohistochemical studies for HMB-45 (+), MelanA (+), Micro-ophthalmia TF(+) are helpful. Extrarenal extension, renal vein or lymph node involvement by an otherwise classic AML does not imply a malignant behavior. The risk for spontaneous hemorrhage is greater in AML lesions that are larger than 4cm in diameter and during pregnancy. Rare “Epithelioid” AML lesions with cytologic anaplasia, mitosis, necrosis, may have a malignant behavior.
An ongoing trial targeting the mTOR pathway with Rapamycin agent is underway for AML lesions in the setting of TSC syndrome given the implicated role of TSC1/TSC2 loss in the dysregulation of the above pathway.
Reference(s):
– Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. Virchows Arch. 2008 Feb;452(2):119-32.Incorrect
Answer: Angiomyolipoma (AML)
Histology: see below
Discussion: Fat-rich angiomyolipoma are more easily diagnosed as AML on imaging studies and are therefore only rarely resected. Fat-poor examples, like the current case, are more difficult to diagnose especially at the time of frozen section, a point to remember when examining a frozen section from “tumor bed” margin during partial nephrectomy.
A member of the perivascular epithelioid cell (PEComa) group of neoplasms, renal angiomyolipomas (AML) represent 1% of renal masses. One third of AML are associated with tuberous sclerosis (TSC) syndrome. When present, the characteristic histologic triad of thick walled vessels + mature fat + smooth muscle fibers make for an easy diagnosis. However, the occasional presence of focal cytologic pleomorphism especially when coupled with hemorrhage and ensuing necrosis can lead to overdiagnosis as a sarcomatoid renal cell carcinoma. Immunohistochemical studies for HMB-45 (+), MelanA (+), Micro-ophthalmia TF(+) are helpful. Extrarenal extension, renal vein or lymph node involvement by an otherwise classic AML does not imply a malignant behavior. The risk for spontaneous hemorrhage is greater in AML lesions that are larger than 4cm in diameter and during pregnancy. Rare “Epithelioid” AML lesions with cytologic anaplasia, mitosis, necrosis, may have a malignant behavior.
An ongoing trial targeting the mTOR pathway with Rapamycin agent is underway for AML lesions in the setting of TSC syndrome given the implicated role of TSC1/TSC2 loss in the dysregulation of the above pathway.
Reference(s):
– Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. Virchows Arch. 2008 Feb;452(2):119-32.